Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer  by Kristjansdottir, Björg et al.
Gynecologic Oncology 131 (2013) 52–58
Contents lists available at ScienceDirect
Gynecologic Oncology
j ourna l homepage: www.e lsev ie r .com/ locate /ygynoDiagnostic performance of the biomarkers HE4 and CA125 in type I and type II
epithelial ovarian cancer
Björg Kristjansdottir ⁎, Kristina Levan, Karolina Partheen, Karin Sundfeldt
University of Gothenburg, Institute of Clinical Sciences, Department of Obstetrics and Gynecology, S-41345 Gothenburg, Sweden
H I G H L I G H T S
• With HE4 and CA125 we can diagnose the aggressive type II EOC at all stages and ages most correctly.
• The diagnostic safety for the dual markers HE4 and CA125 is not acceptable in early stage type I EOC.
• Our results support that EOC should be looked upon as several different diseases.⁎ Corresponding author. Fax: +46 31 41 87 17.
E-mail addresses: bjorg.kristjansdottir@vgregion.se (B
kristina.levan@gu.se (K. Levan), karolina.partheen@gu.se
karin.sundfeldt@gu.se (K. Sundfeldt).
0090-8258 © 2013 The Authors. Published by Elsevier Inc
http://dx.doi.org/10.1016/j.ygyno.2013.07.094a b s t r a c ta r t i c l e i n f oArticle history:
Received 23 May 2013
Accepted 17 July 2013
Available online 25 July 2013
Keywords:
Epithelial ovarian cancer
CA125
HE4
Type I and type II EOC
Diagnostic biomarkers
Objective. To evaluate the diagnostic performance of HE4 and CA125 in patients presenting with suspicious
malignant ovarian cysts. We especially wanted to investigate the levels of HE4 and CA125 with regard to the
gene and histology-unifying model of type I and type II epithelial ovarian cancer (EOC).
Methods. Plasma from 373women presentingwith a suspiciousmalignant ovarian cyst was collected prior to
surgery. Histology, grade, and stage were determined according to FIGO-classiﬁcation. HE4 and CA125 were
analyzed using ELISA, and the markers were evaluated for signiﬁcance separately and in combination. Receiver
operating curves, the area under the curve, sensitivity and speciﬁcity were estimated.
Results. The combination of HE4 and CA125 resulted in the best diagnostic power in comparing benign tu-
mors to EOC (ROC AUC 0.93, sensitivity 94.4% at 75% speciﬁcity) for type II. Diagnostic power in type I (ROC
AUC 0.79, sensitivity 61.9% at 75% speciﬁcity) was less impressive. In particular, mucinous benign vs. malignant
tumors could not signiﬁcantly be separated by the dual marker combination. Impressively high ROC AUC 0.99
was found for the late stage type II EOC with 100% sensitivity at 75% speciﬁcity.
Conclusions. HE4 and CA125 have a good ability to diagnose the more aggressive type II tumors but a poor
diagnostic ability when patients are presenting with slow-growing type I in the early stage. Our results support
the hypothesis that EOC should be looked upon as several different diseases, and thatwe lack biomarkers for sub-
groups of EOC.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.Introduction
Because of the great heterogeneity in molecular and biological sta-
tus, epithelial ovarian cancer (EOC) is actually many different diseases,
which have different clinical outcomes and may require different treat-
ments [1]. The four major histological subtypes are, based on their
morphologic features, serous, endometrioid, clear cell, and mucinous.
Traditionally EOC has been thought to arise from epithelial cells that. Kristjansdottir),
(K. Partheen),
. Open access under CC BY license.cover the ovary's surface and even more frequently line subserosal
cysts. Recent studies indicate that EOC also arises from the fallopian
tube epithelium and from the endometrium via retrograde menstrua-
tion [2–4]. EOC is the most lethal malignancy with gynecologic origin
in the Western world. The lack of clearly identiﬁed precancerous le-
sions, reliable screening tests, and unspeciﬁc early symptoms results
in late diagnosis. When detected at an early stage (25%) the disease is
highly curable [5].
Based onmorphological andmolecular genetics, a novel tumor orig-
ination and progression model was proposed, which divided EOC into
type I and type II tumors [3,6,7]. Type I tumors are suggested to behave
in an indolentmanner and aremore often conﬁned to the ovary at diag-
nosis, with a stable genome and without TP53 mutations, although so-
matic mutations are frequently detected in a number of genes [8].
Type II tumors are suggested to be more aggressive and genetically
highly instable; the majority have TP53 mutations and almost half of
Table 2
Epithelial ovarian cancer classiﬁcation by type I (n = 42) and type II (n = 71).
GradeHistology Stagea
High Moderate Poor Undiff
Total, n = 113
(100 %)
Mucinous I 5 1 2 8
II 1 1
III 1 1
IV 1 1
Total 7 2 2 Mucinous
11 (9.7)    
Type I
Clear cell I 4 1 5
III 1 1 2
Total 5 1 1 Clear cell 7 (6.2) 
Type I
Serous I 9 7 6 22
II 2 5 7
III 7 8 23 38
IV 2 3 5
Total 18          
type I
17          
type II
37          
type II
Serous 72 (63.7) 
Endometrioid I 4 4 2 10
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[9]. These aggressive tumors account for 75% of all EOC and are respon-
sible for 90% of deaths from the disease [7,10].
In September 2011, the FDA cleared two glycoproteins, human epi-
didymis protein 4 (HE4) and carbohydrate antigen (CA125), to be
used together to estimate the risk for EOC in women with a pelvic
mass. Our group and others have evaluated the marker combination,
and found HE4 to be complementary to CA125 [11,12]. CA125 has
been used in ovarian cancer diagnosis for 30 years and is elevated in ap-
proximately 80% of EOC but for only 50–60% of early stage tumors [13].
HE4 has a stable 4-disulﬁde core protein associated with the WFDC2
gene and was ﬁrst introduced as a potential biomarker for EOC in
2003 [14]. Both CA125 and HE4 have been reported to promote EOC
growth and invasion although themechanism of this action is not clear-
ly deﬁned [15].
In this study, we aimed to evaluate the diagnostic performance of
HE4 and CA125 in blood from patients presenting with suspicious ma-
lignant ovarian cyst. We especially wanted to investigate levels of HE4
and CA125 with regard to the unifying model of type I and type II EOC.II 1 1
III 2 2 2 6
Total 6             
type I
6            
type II
5            
type II
Endometrioid 7 
(15.1)
Undifferentiated I 2
III 4 Undifferentiated
6 (5.3)
Total 24            
type I
23          
type II
42            
type II
6
type II
aAccording to FIGO.Materials and methods
Study population
A total of 393 patients were enrolled in the study. Twenty tumors
were excluded because of non-epithelial ovarian cancer (n = 4; 3
granulosa cell cancers and 1 malignant teratoma) and metastases
(n = 16). The eligible study population (n = 373) comprised women
with benign ovarian tumors (n = 215), borderline tumors (n = 45),
and EOC (n = 113) (Table 1). Menopause status, deﬁned as one year
of amenorrhea, was checked for women between 47 and 56 years of
age. Patients b47 years were considered premenopausal and women
N56 years, postmenopausal. The local ethics committee at Gothenburg
University approved the study protocol, and samples were collected
consecutively from all patients who signed a written formed consent.
After surgery, the tumors were examined by an experienced pathol-
ogist for diagnosis, histology, grade, and stage (I–IV), according to FIGO
standards. The EOC was further divided into type I and type II tumors
[8]. Type I included low-grade (G1) serous, low-grade (G1)
endometrioid, all clear cell, mucinous, and transitional (Brenner) carci-
nomas. Type II included high-grade (G2–G3) serous, high-grade (G2–
G3) endometrioid, undifferentiated carcinoma, and malignant mixed
mesodermal tumors (Table 2) [8].Table 1
Type I and type II patient age, menopause status and tumor characteristics.
Benign Borderline
Pre-M Post-M All (%) Pre-M
Mean age (range) 41 (16–52) 66 (47–88) 60 40 (18–52)
Total 373 (393)a (%) 50 (23.3) 165 (76.7) 215 (57.6) 27 (60)
EOC type I
EOC type II
Histology
Simple 11 36 47 (22)
Endometrioma 5 6 11 (5)
Hemorrhagic 2 2 4 (2)
Stromal 2 11 13 (6) 0
Dermoid 8 4 12 (6) 1
Serous 7 69 76 (35) 17
Mucinous 15 37 52 (24) 8
Endometrioid 1
Clear cell
Undifferentiated
Pre-M = premenopausal; Post-M = postmenopausal.
a =20 tumors were excluded; 3 granulosa cell cancers, 1 malignant teratoma, and 16 metasSample collection and processing and biomarker analyses
Patients were consecutively and prospectively included when ad-
mitted for surgery for a clinically suspicious malignant ovarian cyst at
the Department of Gynecologic Oncology, Sahlgrenska University Hos-
pital, Gothenburg, Sweden, from 2001 to 2010. Inclusion and exclusion
criteria have been speciﬁed earlier along with handling and storage of
samples [11]. ELISA analyses were performed on plasma according to
themanufacturer's instructions (FujirebioDiagnostics, Inc., Gothenburg,
Sweden) [11]. HE4 plasma concentrations were determined using HE4
EIA assay (Fujirebio Diagnostics) and plasma CA125 levels were mea-
sured using Architect CA 125 II (Abbott Diagnostics, USA) at Fujirebio
Diagnostics. The assays were performed on coded samples.Malignant
Post-M All (%) Pre-M Post-M All (%)
65 (47–85) 50 44 (28–56) 65 (48–88) 61
18 (40) 45 (12.1) 21 (18.6) 92 (81.4) 113 (30.3)
9 (21.4) 33 (78.6) 42 (37.2)
12 (17.0) 59 (83.0) 71 (62.8)
1 1 (2)
0 1 (2) 0
7 24 (53) 10 62 72 (64)
10 18 (40) 4 7 11 (10)
0 1 (2) 6 11 17 (15)
0 7 7 (6)
1 5 6 (5)
tases.
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Statistical differences in protein levels between groups were evalu-
ated using the Mann–Whitney U test or the corresponding Kruskal–
Wallis one-way analysis of variance for three or more groups. Cut-off
for CA125 b35 U/mlwas used. For HE4 cut-off values for this study pop-
ulation were calculated in our prior study [11] HE4 71.8 pM premeno-
pausal and 85 pM postmenopausal. Cases with marker levels above
threshold levels were considered to have a positive result. When the
markers were used in combination the test was positive if one of the
markers was positive, and negative if both of the markers were nega-
tive. The predicted probabilities for each model were used to construct
receiver operating characteristic (ROC) curves, and the area under the
curve (AUC) values was calculated. Sensitivity and speciﬁcity were
calculated for individual markers and their combinations and positive
predictive value (PPV) and negative predictive value (NPV) for types I
and II. The natural log of protein levels was included as independent
variables in the logistic regression analysis. For all statistical compari-
sons a value of p b 0.05 was considered signiﬁcant. Statistical analyses
were performed in SPSS for Windows version17.0 (SPSS Inc., Chicago,
IL, USA) and Stata 12.1 (Stata Corp., Texas, USA).Results
Patient material
Of the 373 women eligible for analysis, 58% had benign tumors, 12%
borderline and 30% EOC (Table 1). The malignant tumors were divided
into the slow-growing type I EOC and the more aggressive type II EOCTable 3
HE4 and CA125 levels according to histology, type, stage and menopause status; signiﬁcant d
positive predictive value (PPV) and negative predictive value (NPV).
Benign Type I EOC
Median
(range)
Median
(range)
p-Value ROC AUC
(95%CI)
Sensitivitya
(%)
CA125 16
(2–4632)
53
(8–3250)
b0.001 0.76
(0.68–0.85)
71.4
Pre-M 23
(6–121)
40
(22–146)
0.076 0.78
(0.64–0.91)
55.6
Post-M 14
(2–4632)
64
(8–3250)
b0.001 0.76
(0.66–0.86)
66.7
Early stageb 36
(8–2932)
b0.001 0.70
(0.60–0.81)
62.0
Late stageb 194
(8–3250)
b0.001 0.9
(0.77–1.00)
92.3
HE4 66
(31–469)
93
(40–784)
b0.001 0.72
(0.63–0.81)
54.8
Pre-M 57
(31–469)
73
(46–190)
1.0 0.71
(0.52–0.90)
55.6
Post-M 69
(34–631)
109
(0.87–0.96)
b0.001 0.73
(0.63–0.83)
60.6
Early stageb 74
(40–785)
b0.001 0.66
(0.54–0.77)
45.0
Late stageb 129
(66–642)
b0.001 0.86
(0.77–0.95)
76.9
HE4 + CA125 0.79
(0.72–0.86)
61.9
Pre-M 0.80
(0.67–0.93)
44.4
Post-M 0.79
(0.71–0.88)
66.7
Early stageb 0.73
(0.64–0.82)
48.3
Late stageb 0.93
(0.87–0.99)
92.3
Early stage = I + II, late stage = III + IV; pre-M = premenopausal, post-M = postmenopau
a Sensitivity set at 75% speciﬁcity.
b According to FIGO staging.by histology and grade (Table 2). Type I included low-grade serous
(n = 18; 42%), low-grade endometrioid (n = 6; 14%), all mucinous
(n = 11; 26%) and all clear cell (n = 7; 17%). The type II group included
high-grade serous (n = 54; 76%), high-grade endometrioid (n = 11;
15.5%), and undifferentiated carcinomas (n = 6; 8.5%). The mean age
was equally distributed within the benign and EOC cohorts, type I and
type II, while the mean age for the borderline tumors was 10 years
younger (60% premenopausal). Most of the women with EOC (81.4%)
were postmenopausal, 79% in type I and 83% in type II, and the benign
cohort included 78% postmenopausal women (Table 1). The median
values and range of HE4 and CA125 in all subgroups are found in the
Supplement (S1).Signiﬁcantly different levels of HE4 and CA125 in the type I and type II
cohorts
HE4 and CA125 signiﬁcantly separated (p b 0.001) the type I and
type II cohorts from the benign cohort, and CA125 levels were signiﬁ-
cantly (p b 0.001) different between the benign and borderline tumors,
but not HE4 (p = 1.0) (Table 3) (Fig. 1A + B). Both biomarkers were
also able to separate type I from type II, and borderline from type II tu-
mors (p b 0.001). However, neither HE4 (p = 0.026) nor CA125 (p =
1.000) was signiﬁcant when borderline tumors were compared to
type I EOC. The median value in benign tumors for HE4 was 66 pM
and increased to 93 pM and 354 pM in type I and type II. The increase
was evenmore notable for CA125wheremedian value of CA125 ranged
from 16 U/ml in benign patients to 53 U/ml in type I and 395 U/ml in
type II (Table 3, Fig. 1A + B). The ROCAUCwas, according to these ﬁnd-
ings, high for type II EOC (0.92 HE4; 0.93 CA125; 0.93 HE4 + CA125),ifferences, ROC AUC and sensitivity at 75% speciﬁcity in benign vs. type I and type II, and
Type II EOC
PPV/NPV Median
(range)
p-Value ROC AUC
(95%CI)
Sensitivity
(%)
PPV/NPV
39.1/92.0 395
(6–14,880)
b0.001 0.93
(0.89–0.97)
93 60.7/96.6
731
(20–4232)
b0.001 0.90
(0.78–1.00)
83.3
327
(6–14,880)
b0.001 0.93
(0.89–0.97)
96.6
104
(6–2430)
b0.001 0.85
(0.76–0.94)
81.5
564
(50–14,880)
b0.001 0.98
(0.96–0.99)
100
30.2/90.6 354
(39–7933)
b0.001 0.92
(0.87–0.96)
91.5 52.0/96.3
239
(41–1732)
b0.001 0.91
(0.77–1.00)
91.7
412
(39–7932)
b0.001 0.91
(0.86–0.96)
91.5
132
(39–1730)
b0.001 0.81
(0.71–0.92)
81.5
474
(76–7932)
b0.001 0.98
(0.96–1.00)
97.7
31.3/95.2 0.93
(0.89–0.98)
94.4 46.5/97.2
0.92
(0.79–1.00)
83.3
0.94
(0.89–0.98)
93.2
0.85
(0.75–0.95)
85.2
0.99
(0.98–1.00)
100
sal.
Fig. 1. Box plot for (A) CA125 levels (reference line at cut-off 35 U/ml), by benign, type I and type II EOC; (B) HE4 levels (reference line at cut-off 85 pM) by benign, type I and type II EOC;
(C) CA125 levels for each type divided into early stage (FIGO I/II) and late stage (FIGO III/IV); (D) HE4 levels for each type divided into early stage (FIGO I/II) and late stage (FIGO III/IV);
logarithmic scale; (E) ROC AUC for HE4, CA125, and HE4 + CA125 by benign and type I EOC; and (F) for HE4, CA125 and HE4 + CA125 by benign and type II EOC.
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when benign tumors were compared to type I EOC (Fig. 1C + D).
In EOC false negatives are feared. We located 13 false negatives, de-
ﬁned as negative by both biomarkers, all in the early stage: type I
(n = 9; 5 low-grade serous, 2 mucinous, 1 endometrioid, and 1
clear cell EOC) and type II (n = 4; high-grade serous FIGO stage I).
Sensitivity for HE4 and CA125 individually in type II was 91.5% and
93%, respectively, and in type I 54.8% and 71.4%, calculated at 75%
speciﬁcity (Table 3). Sensitivity for type II EOC was improved(94.4%) when using the dual markers, but not in type I (61.9%),
where CA125 was better used alone.
HE4 + CA125 evaluation in early and late stage type I and type II EOC
In the next step we wanted to evaluate the performance of HE4 and
CA125 according to FIGO stages. Type I was divided into early stage
(FIGO I + II; n = 29) 69% and late stage (FIGO III + IV; n = 13) 31%,
and type II early stage (n = 27) 38% and late stage (n = 44) 62%, and
Fig. 2. (A) ROCAUC forHE4 + CA125by benign and early (I–II) type I EOC and (B) by benign and late (III–IV) type I; (C) ROCAUC for HE4 + CA125 bybenign andearly type II EOC and (D)
by benign and late type II.
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differences were noted in all comparisons (Table 3, Fig. 2A–B). The
median values for HE4 in early stage type I and type II EOC were
74 pM and 132 pM and in late stage were 129 pM and 474 pM re-
spectively. The median values for CA125 in early stage type I and
type II EOC were 36 U/ml and 104 U/ml and in late stage were
194 U/ml and 564 U/ml, respectively. The ROC AUC was impressive-
ly high (0.99) for HE4 +CA125 when comparing benign to late stage
type II EOC and was 0.93 in type I. However, ROC AUC was just 0.85,
for the clinically more sought early stage diagnostic of type II EOC
and only 0.73 for type I (Fig. 2C–D). With respect to the small
group size, sensitivity in early and late stage type II was 85.2% and
100% and in early and late stage type I was 48.3% and 92.3%, calculat-
ed at 75% speciﬁcity.HE4 + CA125 evaluation in pre- and postmenopausal type I and type II
EOC
We then hypothesized that the dual biomarker combination
would perform even worse in premenopausal than in women in post-
menopause, within type I and II compared to the benign cohort
(Fig. 3). Statistically signiﬁcant (p b 0.001) differences were found be-
tween all groups except for the premenopausal type I EOC (n = 9) vs.
benign (Table 3). The combination of HE4 and CA125 resulted in the
best ROC AUC estimates, with better value in type II, but without differ-
ences within each type: benign vs. type I pre- and postmenopausal
women (0.80 and 0.79) and benign vs. type II pre- and postmenopausal
(0.92 and 0.94).Evaluation of HE4 and CA125 levels according to EOC histological subtype
The division of EOC into the proposed type I and type II tumors
is based on new evidence of genetic changes in EOC histologic
subgroups. As the above data shows, the dual markers could not
diagnose type I EOC. Further subgrouping and analysis of the
EOC type I into mucinous, endometrioid, serous type I and serous
type II was performed. Low HE4 median value was detected in
mucinous carcinomas (88 pM) and in clear cell carcinomas
(129 pM), while HE4 for endometrioid and serous carcinomas
was higher (171 pM and 322 pM) and the highest for undifferen-
tiated tumors (629 pM). The median CA125 value was as well as
for HE4 lowest in mucinous carcinomas (36 U/ml), with increas-
ing values in endometrioid (132 U/ml), clear cell (194 U/ml),
and serous carcinomas (297 U/ml) and highest in undifferentiat-
ed carcinomas (1304 U/ml) (details are found in S1). Both bio-
markers were signiﬁcantly different (HE4 p = 0.0045, CA125
p = 0.0002) in comparing benign serous tumors to serous type I
and serous type II EOC (p =0.0001). Signiﬁcant differences within
serous borderline tumors, type I and type II were estimated.
CA125 was signiﬁcantly different between these tumors, but not
HE4 (p = 0.0001 and 0.569). However, HE4, but not CA125, was
signiﬁcantly increased (p = 0.003 and p = 1.0) in serous type I
compared to serous borderline tumors. Neither HE4 nor CA125
showed signiﬁcance comparing mucinous adenoma and borderline
tumors and mucinous EOC (S1). As expected, HE4, but not CA125,
was signiﬁcant (p = 0.0019 and p = 0.1380) when comparing be-
nign endometrioma from endometrioid EOC, more often negative
in endometrioma.
p=0.0045*
NA
NA
NA
NA
p<0.0001**p=0.0019 p=0.728
p=0.0002*
p<0.0001**p=0.1380 p=0.09
A
B
Fig. 3. (A) Scatter plot for HE4 in different histology of EOC and (B) for CA125; logarithmic
scale.
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It has been suggested that EOC, which traditionally is subgrouped
according to histology, should be subgrouped with regard to molecular
genetic changes into slow-growing type I and aggressive type II EOC [8].
The rarity of ﬁnding early stage high-grade serous tumors (type II) has
made it difﬁcult to study pre-malignant and early stage lesions.
Detecting these most threatening tumors is challenging [16,17]. In this
study, we aimed to evaluate the diagnostic performance of the bio-
markers HE4 and CA125 alone or combined in type I and type II EOC.
We used a cohort of 373 patient blood samples that were consecutively
and prospectively collected from women scheduled for surgery for a
malignant suspicious cystic ovarian mass [11] and can conclude that
HE4 and CA125 are highly representative markers for type II EOC. The
combination of HE4 and CA125 resulted in the best diagnostic power
with ROC AUC 0.93 and NPV 97.2 for type II EOC, and impressively
high AUC 0.99 for late stage type II EOC in comparison to the benign co-
hort. But as mentioned above aggressive early stage serous EOC is in
need to be correctly diagnosed, still in our study we missed four out of
six. In addition, none of the markers alone or in combination had a
good diagnostic ability for all type I EOC. Lu et al. tested fourteen sero-
logic markers to discriminate type I and II EOC in a similar setting;
CA125 had the greatest power of the tested markers with AUC 0.93 in
type II and AUC 0.89 in type I. This is about the same as for CA125 in
this study (HE4 was not included in the Lu et al. study) [18]. To ourknowledge, HE4 has not earlier been evaluated by dividing EOC into
type I and type II. Other reports and our previous reports have mainly
studied the diagnostic performance of HE4 and CA125 in groups of all
EOC compared to benign cohorts and have found less diagnostic
power (AUC b0.90) [11,12]. We believe that this is due to the poor per-
formance of the dual biomarkers in type I EOC found in this study. We
suggest that research is needed with a focus on new histology-speciﬁc
markers to correctly diagnose each subgroup.
The suggested division into type I and type II on a 2-tier grading sys-
temwas done based on biologic evidence that indicated that low-grade
and high-grade EOC developed via different pathways. Both high-grade
serous and endometrioid EOC are genetically unstable, contain P53mu-
tation, and behave aggressively. In contrast, low-grade tumors have a
relatively stable genome and are more often conﬁned to the ovaries at
diagnosis [3,7]. This is a simpliﬁed model, putting the focus on the
most aggressive EOC, the majority of all ovarian cancers. Recent studies
have suggested that an evenmore individualized subgroupingmight be
needed [1,19]. In our study, themedian age among EOC type I and II was
the same. Age, reﬂected by dividing type I and type II into pre- and post-
menopausal groups, did not inﬂuence ROC AUC within each group
[14,20]. The high number (78%) of postmenopausalwomenwith benign
disease and the overall low number of premenopausal womenmay ex-
plain the relatively high age of the benign cohort. The performance of
the biomarker combination was only inﬂuenced by stage within each
type.
The ultimate goal to increase survival in EOC is ﬁnding early stage le-
sions regardless of type. In this study, early stage EOC comprised 50% of
the malignant cohort (26% type I and 24% type II), which is more than
expected [7,19]. The large numbers with early EOC may be due to one
of the inclusion criteria: the presence of cystic ovarian pelvic mass and
not just any pelvic mass. The dual biomarkers tested in this study were
inferior in type I EOC diagnostics but seem to be an asset in the diagnosis
of type II EOC. Tumors in the type I subgroup are generally of a larger size,
more often localized in the pelvis, and therefore, more easily detected at
an earlier stage with conventional techniques (such as clinical examina-
tion including gynecological bimanual palpation, transvaginal and ab-
dominal ultrasound and computed tomography scanning) than type II
EOC, which might not have visible early lesion [21].
It has been argued that the aggressive type II EOC,whichmostly con-
sists of tumorswith serous histology,would beneﬁtmost frombeingde-
tected at early stages [18]. In our previous study, CA125 showed better
diagnostic ability than HE4 (AUC HE4 0.72 and CA125 0.76) when com-
paring benign to stage I EOC (n = 47/113). In contrast, HE4 could diag-
nose stage I EOC better than CA125 in studies by Moore (n = 13/67)
and Van Gorp (n = 43/131) (AUC HE4 0.77/CA125 0.70 and AUC HE4
0.77/CA125 0.75). The three studies differed in number of included pa-
tients and the patients had different characteristics. This study was the
only one that included women with cystic tumors, while Van Gorp's
and Moore's cohorts had a higher percentage of premenopausal
women and late stage EOC [11,12,22]. In addition, Van Gorp had 29% en-
dometriosis in the benign groupwhich, together with the young cohort,
could theoretically increase the diagnostic capacity of HE4. However,
the largest published and still ongoing Danish study present data from
1218 patients referred to a tertiary center because of a pelvic mass
with high and equal capacity for both markers in diagnosing early
stage tumors (n = 64/252 EOC) AUC HE4 0.86 and CA125 0.85 [23].
HE4 levels in blood and gene expression vary between different
malignant histological groups with the highest values for tumors
representing type II tumors [24,25]. We found signiﬁcant variations in
HE4 and CA125 levels within different tumors and histotypes, and as
expected, the highest levels were in the tumors representing type II
(S1). HE4 could signiﬁcantly separate endometrioma fromendometrioid
EOC but none of the markers could separate benign and borderline mu-
cinous tumors frommucinous EOC. This is in keepingwith several recent
papers,whichmainly investigated EOC in late stages [22,24,26]. Great di-
agnostic power for serum CA125 (AUC 0.99) and HE4 (AUC 0.98) for
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mucinous tumors [24,26]. Drapkin et al. demonstrated 93% expression of
HE4 in high-grade serous, 100% in high-grade endometrioid, and 50% in
clear cell, but no staining in mucinous when studying 92 late stage EOC
[25].
Type I EOC is a group of rare and individually different tumors that
need attention.Mucinous tumors can still be challenging to differentiate
using vaginal ultrasound; even during an expert pathologic examina-
tion, metastases from the gastrointestinal tract of mucinous histology
are often mistaken for ovarian cancer [1,27]. Though belonging to type
I EOC, clear cell and mucinous tumors are quite aggressive, particularly
at late stages with an even higher mortality than type II [19,28]. Finding
early markers that are speciﬁc for all histology subgroups is a future
challenge. Achieving a better understanding of the pathogenesis,molec-
ular biology, and behavior of the EOC is crucial tomove forward the pro-
cess of improving early diagnosis and survival for patients with EOC.
Conclusion
Using HE4 and CA125 we can more accurately diagnose the aggres-
sive type II, than the type I EOC. The diagnostic safety for the dual
markers HE4 and CA125 is not acceptable in early stage type I EOC.
Our results support the hypothesis that EOC should be looked upon as
several different diseases. Finding early markers that are speciﬁc for all
histologic subgroups will be our future challenge.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygyno.2013.07.094.
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